It is a well known fact that the combination of antidiabetic and anticoagulant medications can result in adverse drug events.
Type II Diabetes patients taking glipizide or glimepiride may be at greater risk of hypoglycaemia if they are started on warfarin, according to a large US study published in the BMJ by Romley et al in 2015. In this study, 15% of patients were on dual medications of sulfonyurea and warfarin.
The mechanism of action for an interaction between warfarin and glipizide/glimepiride is unclear. It is thought that the interaction may occur through displaced protein binding or through competition for the CYP2C9 hepatic metabolic pathway.
Furthermore, the food and nutrition advice is also an important consideration, as monitoring the patient’s carbohydrate goals and levels of Vitamin K is crucial.
Type II Diabetes patients taking glipizide or glimepiride may be at greater risk of hypoglycaemia if they are started on warfarin, according to a large US study published in the BMJ by Romley et al in 2015. In this study, 15% of patients were on dual medications of sulfonyurea and warfarin.
The mechanism of action for an interaction between warfarin and glipizide/glimepiride is unclear. It is thought that the interaction may occur through displaced protein binding or through competition for the CYP2C9 hepatic metabolic pathway.
Furthermore, the food and nutrition advice is also an important consideration, as monitoring the patient’s carbohydrate goals and levels of Vitamin K is crucial.